These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28203756)

  • 1. Non-canonical roles of Bcl-2 and Bcl-xL proteins: relevance of BH4 domain.
    Gabellini C; Trisciuoglio D; Del Bufalo D
    Carcinogenesis; 2017 Jun; 38(6):579-587. PubMed ID: 28203756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BH4 domain of Bcl-2 as a novel target for cancer therapy.
    Liu Z; Wild C; Ding Y; Ye N; Chen H; Wold EA; Zhou J
    Drug Discov Today; 2016 Jun; 21(6):989-96. PubMed ID: 26631752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death.
    Inohara N; Gourley TS; Carrio R; Muñiz M; Merino J; Garcia I; Koseki T; Hu Y; Chen S; Núñez G
    J Biol Chem; 1998 Dec; 273(49):32479-86. PubMed ID: 9829980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4.
    Huang DC; Adams JM; Cory S
    EMBO J; 1998 Feb; 17(4):1029-39. PubMed ID: 9463381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYD0281, a Bcl-2 BH4 domain antagonist, inhibits tumor angiogenesis and breast cancer tumor growth.
    Lin Y; Zhao Y; Chen M; Li Z; Liu Q; Chen J; Ding Y; Ding C; Ding Y; Qi C; Zheng L; Li J; Zhang R; Zhou J; Wang L; Zhang QQ
    BMC Cancer; 2023 May; 23(1):479. PubMed ID: 37237269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel Bcl-x splice product, Bcl-xAK, triggers apoptosis in human melanoma cells without BH3 domain.
    Hossini AM; Geilen CC; Fecker LF; Daniel PT; Eberle J
    Oncogene; 2006 Apr; 25(15):2160-9. PubMed ID: 16288206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteins of the bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities.
    Chan SL; Yu VC
    Clin Exp Pharmacol Physiol; 2004 Mar; 31(3):119-28. PubMed ID: 15008953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Bcl-2 family: structures, interactions and targets for drug discovery.
    Kvansakul M; Hinds MG
    Apoptosis; 2015 Feb; 20(2):136-50. PubMed ID: 25398535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional dissection of Bfl-1, a Bcl-2 homolog: anti-apoptosis, oncogene-cooperation and cell proliferation activities.
    D'Sa-Eipper C; Chinnadurai G
    Oncogene; 1998 Jun; 16(24):3105-14. PubMed ID: 9671389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and function of a proapoptotic Bcl-2 family member Bcl-XL/Bcl-2-associated death promoter (BAD) in rat ovary.
    Kaipia A; Hsu SY; Hsueh AJ
    Endocrinology; 1997 Dec; 138(12):5497-504. PubMed ID: 9389536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death.
    Reed JC; Zha H; Aime-Sempe C; Takayama S; Wang HG
    Adv Exp Med Biol; 1996; 406():99-112. PubMed ID: 8910675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond.
    Monaco G; Vervliet T; Akl H; Bultynck G
    Cell Mol Life Sci; 2013 Apr; 70(7):1171-83. PubMed ID: 22955373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis induction by Bcl-2 proteins independent of the BH3 domain.
    Hossini AM; Eberle J
    Biochem Pharmacol; 2008 Dec; 76(11):1612-9. PubMed ID: 18778689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and identification of a novel small molecule BCL-2 inhibitor that binds to the BH4 domain.
    Zhou JY; Yang RR; Chang J; Song J; Fan ZS; Zhang YH; Lu CH; Jiang HL; Zheng MY; Zhang SL
    Acta Pharmacol Sin; 2023 Feb; 44(2):475-485. PubMed ID: 35918411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mtd, a novel Bcl-2 family member activates apoptosis in the absence of heterodimerization with Bcl-2 and Bcl-XL.
    Inohara N; Ekhterae D; Garcia I; Carrio R; Merino J; Merry A; Chen S; Núñez G
    J Biol Chem; 1998 Apr; 273(15):8705-10. PubMed ID: 9535847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative genomics: the evolutionary history of the Bcl-2 family.
    Lanave C; Santamaria M; Saccone C
    Gene; 2004 May; 333():71-9. PubMed ID: 15177682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition.
    Gabellini C; De Luca T; Trisciuoglio D; Desideri M; Di Martile M; Passeri D; Candiloro A; Biffoni M; Rizzo MG; Orlandi A; Del Bufalo D
    Carcinogenesis; 2013 Nov; 34(11):2558-67. PubMed ID: 23836782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ryanodine receptors are targeted by anti-apoptotic Bcl-XL involving its BH4 domain and Lys87 from its BH3 domain.
    Vervliet T; Lemmens I; Vandermarliere E; Decrock E; Ivanova H; Monaco G; Sorrentino V; Nadif Kasri N; Missiaen L; Martens L; De Smedt H; Leybaert L; Parys JB; Tavernier J; Bultynck G
    Sci Rep; 2015 Apr; 5():9641. PubMed ID: 25872771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer cell death strategies by targeting Bcl-2's BH4 domain.
    de Ridder I; Kerkhofs M; Veettil SP; Dehaen W; Bultynck G
    Biochim Biophys Acta Mol Cell Res; 2021 Apr; 1868(5):118983. PubMed ID: 33549704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ectopic expression of Bcl-XL or Ku70 protects human colon cancer cells (SW480) against curcumin-induced apoptosis while their down-regulation potentiates it.
    Rashmi R; Kumar S; Karunagaran D
    Carcinogenesis; 2004 Oct; 25(10):1867-77. PubMed ID: 15205359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.